Recombinant human endostatin Phase I clinical study.docVIP

 PAGE \* MERGEFORMAT 8 Recombinant human endostatin Phase I clinical study Author; Tong Zhongsheng, Yan Zhao, Pakistan 1, Shu-Fen Lee, Shi Ye-hui, HE Li-hong, WANG Xu, WANG Chen, Hao Chunfang [Abstract] Objective To evaluate recombinant human endostatin in human safety and pharmacokinetic characteristics. Methods 27 cases of healthy volunteers were divided into four dose groups, respectively, 30 mg/m2 (3 Li), 60 mg/m2 (8 Li), 120 mg/m2 (8 Li), 180 mg/m2 (8 Li ), all single intravenous infusion of recombinant human endostatin; 16 cases of malignant tumor patients, sub-3 dose groups, resp